# A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

> **NCT03607422** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 912 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Placebo for Upadacitinib
- **DRUG:** Upadacitinib

## Key facts

- **NCT ID:** NCT03607422
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-27
- **Primary completion:** 2021-03-11
- **Final completion:** 2025-11-11
- **Target enrollment:** 912 (ACTUAL)
- **Last updated:** 2025-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03607422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03607422, "A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03607422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*